<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F20FFE5B-3DA6-4629-894F-4CE13B49B4E4"><gtr:id>F20FFE5B-3DA6-4629-894F-4CE13B49B4E4</gtr:id><gtr:name>Vanderbilt University</gtr:name><gtr:address><gtr:line1>Vanderbilt University</gtr:line1><gtr:line2>2201 West End Avenue</gtr:line2><gtr:line4>Nashville</gtr:line4><gtr:line5>Tennessee</gtr:line5><gtr:postCode>TN 37235</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Biochemistry</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F20FFE5B-3DA6-4629-894F-4CE13B49B4E4"><gtr:id>F20FFE5B-3DA6-4629-894F-4CE13B49B4E4</gtr:id><gtr:name>Vanderbilt University</gtr:name><gtr:address><gtr:line1>Vanderbilt University</gtr:line1><gtr:line2>2201 West End Avenue</gtr:line2><gtr:line4>Nashville</gtr:line4><gtr:line5>Tennessee</gtr:line5><gtr:postCode>TN 37235</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/29CB1681-5F41-44ED-AC98-037EEA5991C1"><gtr:id>29CB1681-5F41-44ED-AC98-037EEA5991C1</gtr:id><gtr:firstName>Philip</gtr:firstName><gtr:surname>Biggin</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FL026287%2F1"><gtr:id>001B0253-3D50-4B32-96A6-FB2053B10195</gtr:id><gtr:title>FLIP: Towards Rational Discovery of Biased GPCR Ligands</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/L026287/1</gtr:grantReference><gtr:abstractText>Not required</gtr:abstractText><gtr:technicalSummary>Not required</gtr:technicalSummary><gtr:potentialImpactText>Not required</gtr:potentialImpactText><gtr:fund><gtr:end>2016-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2014-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>86188</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Neusentis Pfizer</gtr:department><gtr:description>Pfizer Neusentis</gtr:description><gtr:id>8FDCD591-0C64-476E-9749-3F0852226374</gtr:id><gtr:impact>There is a manuscript in preparation which will be submitted before Christmas. The collaboration is multidisciplinary and has the following disciplines:-

Organic chemistry (synthesis)
Computational chemistry (modelling and dynamics)
Biochemistry (assays</gtr:impact><gtr:outcomeId>545f5da6284967.24455307-1</gtr:outcomeId><gtr:partnerContribution>The partners have matched pair assay data for a large series of compounds against both these receptors.</gtr:partnerContribution><gtr:piContribution>We have performed the molecular modelling on 5HT2C G-protein signalling biased agonists. In this case, we are trying to rationalize the selectivity between the 5HT2C/5HT2B receptors.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Vanderbilt University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Biased Ligands</gtr:description><gtr:id>F393C15A-5B00-46E6-99C4-92A9C8B6001F</gtr:id><gtr:impact>None yet - the collaboration has only formed in the past 4 months.</gtr:impact><gtr:outcomeId>544e56a621db32.13556541-1</gtr:outcomeId><gtr:partnerContribution>Structural information.</gtr:partnerContribution><gtr:piContribution>We have partnered up to provide modelling insight onto structural information into biased signalling.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Heifetz - Cambridge (UK SAR</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AAC704BD-8470-4E65-B705-2774A0F99FE6</gtr:id><gtr:impact>Dr Heifetz presented the results from our FLIP collaboration at this international conference. The talk was well-received by audience members.</gtr:impact><gtr:outcomeId>56dd4cc08ecf61.56838278</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.ukqsar.org/2015/06/19/auumn-2015-meeting-6th-october-duxford/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Heifetz - Oxford (MGMS)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C90EDE1D-CB5A-48BA-90B3-3D749B3F2F31</gtr:id><gtr:impact>Dr Heifetz presented results from our FLIP collaboration at this international meeting held in Oxford. He was an invited speaker.</gtr:impact><gtr:outcomeId>56dd4b1469f702.97696735</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://sbcb.bioch.ox.ac.uk/mgms2015</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>5th RSC/SCI Symposium on GPCRs in Medicinal Chemistry</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3F143F28-246F-4870-A49A-D1265FEE7CAA</gtr:id><gtr:impact>This was a poster presentation and there was much discussion afterwards about our work.

This stimulated some more discussion about our approach to these problems and indeed questions of how broadly applicable they were.</gtr:impact><gtr:outcomeId>545f5aee37d4c0.59505491</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.rsc.org/Membership/Networking/InterestGroups/BMCS/GPCRs2014.asp</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Heifetz - Berlin meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>592722EC-9A3A-4F15-B62D-232AC0774DC7</gtr:id><gtr:impact>Dr Heifetz was an international speaker at the GTC 2rd GPCR Targeted Screening Conference on GPCRs. Discussions afterwards from several industry colleagues led to new ideas and an invitation to write a review in 2016.</gtr:impact><gtr:outcomeId>56dd4bbfe04db7.75425334</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Heifetz - Prato (GPCRs: Beyond Structure Towards Biochemical Society Conference Monash University Italy)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CB3240FB-1940-4D4A-9846-1DE57B9FFB5F</gtr:id><gtr:impact>Dr Heifetz was an invited speaker at this international GPCR meeting. The invitation arose from his talk in Oxford earlier in the year.</gtr:impact><gtr:outcomeId>56dd4c447e0972.17331545</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.biochemistry.org/Events/tabid/379/MeetingNo/SA173/view/Conference/Default.aspx</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>8420</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MPLS NIF FUND</gtr:description><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>BED31D02-DB99-42B1-82EF-A3821DDA3595</gtr:id><gtr:outcomeId>58bd8bf582ef26.92996986</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The findings from some of the work performed as part of this project are being used in within Evotec Ltd by Dr Heifetz. Clearly some of those projects are confidential so the details must remain sparse at this stage.</gtr:description><gtr:firstYearOfImpact>2016</gtr:firstYearOfImpact><gtr:id>B345949E-27DE-4177-B20C-6A7742234057</gtr:id><gtr:impactTypes/><gtr:outcomeId>545e7fae7124e5.95436884</gtr:outcomeId><gtr:sector>Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>Through the project we have been developing and assessing a new tool that can give better insight into the interactions between a ligand and a receptor protein. Some of these interactions were previously underestimated (or not reported) and so our approach should be very useful in the context of evaluating more accurately how any one particular drug molecule interacts with its partner protein. In particular we have use a method called the Fragment Molecular Orbital (FMO) method which can provide a very detailed level of information on interactions between ligand and protein.</gtr:description><gtr:exploitationPathways>We have shown how a new quantum mechanics approach can offer genuinely new insight into the nature of ligand-receptor interactions. Many colleagues around the world have contacted us to say that is has provided them with a new tool for drug discovery.</gtr:exploitationPathways><gtr:id>1F577609-9104-4338-A253-985EED3185FA</gtr:id><gtr:outcomeId>545e80788687b7.92919216</gtr:outcomeId><gtr:sectors><gtr:sector>Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>GLAS (GPCR Likeness Assessment Score) is an analysis tool that was developed by Dr Heifetz, prior to the award of the FLIP award. Since the award of the FLIP we have been collaborating with the CCPBioSim consortium to expand the tool for use across different HPC platforms. The explosion in the structural biology for GPCRs means that many researchers around the world are examining the dynamic behaviour of these drug targets now and new tools are required to help analyse the results. The GLAS tool provides an easy way to assess the quality of simulation structures in relation to known cyrstallographic data.</gtr:description><gtr:id>D356DB63-9315-42BE-9222-958CC1296AFD</gtr:id><gtr:impact>It is still in development, so we cannot assess the impact directly at this moment in time.</gtr:impact><gtr:outcomeId>545f52484462f7.76396895</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>GLAS</gtr:title><gtr:type>Data analysis technique</gtr:type><gtr:url>http://pubs.acs.org/doi/abs/10.1021/bi401119m</gtr:url></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>5C6DB4C4-79E5-4DC4-935F-AB00B3A16D6D</gtr:id><gtr:title>Beyond Membrane Protein Structure: Drug Discovery, Dynamics and Difficulties.</gtr:title><gtr:parentPublicationTitle>Advances in experimental medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b74d6208a323e3a0efc62611f7e79a0"><gtr:id>9b74d6208a323e3a0efc62611f7e79a0</gtr:id><gtr:otherNames>Biggin PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0065-2598</gtr:issn><gtr:outcomeId>5a9c1373bf3e42.70686834</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05B07E39-1150-4CD2-908D-5C0B7A47FFD2</gtr:id><gtr:title>Guiding lead optimization with GPCR structure modeling and molecular dynamics.</gtr:title><gtr:parentPublicationTitle>Current opinion in pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0e05e0105e572646df2303f64b894c5"><gtr:id>e0e05e0105e572646df2303f64b894c5</gtr:id><gtr:otherNames>Heifetz A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-4892</gtr:issn><gtr:outcomeId>58877621c4d935.50580387</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5AB272B2-F242-487C-9396-A77B1D639061</gtr:id><gtr:title>The Fragment Molecular Orbital Method Reveals New Insight into the Chemical Nature of GPCR-Ligand Interactions.</gtr:title><gtr:parentPublicationTitle>Journal of chemical information and modeling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0e05e0105e572646df2303f64b894c5"><gtr:id>e0e05e0105e572646df2303f64b894c5</gtr:id><gtr:otherNames>Heifetz A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1549-9596</gtr:issn><gtr:outcomeId>56da2d91e79788.12126005</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C3AF905-32D5-4102-AF4E-9CC411C3DA03</gtr:id><gtr:title>Application of an Integrated GPCR SAR-Modeling Platform To Explain the Activation Selectivity of Human 5-HT2C over 5-HT2B.</gtr:title><gtr:parentPublicationTitle>ACS chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0e05e0105e572646df2303f64b894c5"><gtr:id>e0e05e0105e572646df2303f64b894c5</gtr:id><gtr:otherNames>Heifetz A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1554-8929</gtr:issn><gtr:outcomeId>56da2ea5b8bfd7.83844386</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C011C79-574D-4EF0-8CF3-DD147208F84F</gtr:id><gtr:title>Using the fragment molecular orbital method to investigate agonist-orexin-2 receptor interactions.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0e05e0105e572646df2303f64b894c5"><gtr:id>e0e05e0105e572646df2303f64b894c5</gtr:id><gtr:otherNames>Heifetz A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>58877531ef48d7.80774663</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9F37454-F145-4FCF-A23B-90B0B930CE80</gtr:id><gtr:title>GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1-2 September 2014.</gtr:title><gtr:parentPublicationTitle>Naunyn-Schmiedeberg's archives of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0e05e0105e572646df2303f64b894c5"><gtr:id>e0e05e0105e572646df2303f64b894c5</gtr:id><gtr:otherNames>Heifetz A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-1298</gtr:issn><gtr:outcomeId>5568197c7886a1.44318500</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D05EE078-C340-4089-9F34-4BAD88AF6618</gtr:id><gtr:title>Discovery of the First Selective, Nonpeptidic Orexin 2 Receptor Agonists.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0e05e0105e572646df2303f64b894c5"><gtr:id>e0e05e0105e572646df2303f64b894c5</gtr:id><gtr:otherNames>Heifetz A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>56d9d41359f345.17246893</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/L026287/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>F442B6BE-8B89-4C01-8D3B-E8A4D320B672</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Biomolecules &amp; biochemistry</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>A442BF36-F335-483E-9282-F3BB48AC2C47</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Cell biology</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>FB535BD0-E265-4C0A-8532-32DCB83A3951</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Tools, technologies &amp; methods</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>D22AE401-1C35-4706-A19C-10861ABC82CD</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Biological membranes</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>DDA3AC5B-B4B5-4323-988E-62B85A8966BF</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Receptors</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>3493671D-A4CF-4197-90A7-3CCFBE1C0627</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Tools for the biosciences</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>